Phenserine

Bibliography

• HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353-356.
   PubMed Web of Science ®Google Scholar
• NEVE RL, ROBAKIS NK: Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci. (1998) 21:15-19.
   PubMed Web of Science ®Google Scholar
• WALSH DM, SELKOE DJ: Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron (2004) 44:181-193.
   PubMed Web of Science ®Google Scholar
• NASLUND J, HAROUTUNIAN V, MOHS R et al.: Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA (2000) 283:1571-1577.
   PubMed Web of Science ®Google Scholar
• KLEIN WL, KRAFFT GA, FINCH CE: Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. (2001) 24:219-224.
   PubMed Web of Science ®Google Scholar
• SMALL DH, MOK SS, BORNSTEIN JC: Alzheimer's disease and Aβ toxicity: from top to bottom. Nat. Rev. Neurosci. (2001) 2:595-598.
   PubMed Web of Science ®Google Scholar
• WIRTHS O, MULTHAUP G, BAYER TA: A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide – the first step of a fatal cascade. J. Neurochem. (2004) 91:513-520.
   PubMed Web of Science ®Google Scholar
• CHAPMAN PF, FALINSKA AM, KNEVETT SG, RAMSAY MF: Genes, models and Alzheimer's disease. Trends Genet. (2001) 17:254-261.
   PubMed Web of Science ®Google Scholar
• ODDO S, CACCAMO A, SHEPHERD JD et al.: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron (2003) 39:409-421.
   PubMed Web of Science ®Google Scholar
• SHINOE T, MATSUI M, TAKETO MM, MANABE T: Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J. Neurosci. (2005) 25:11194-11200.
   PubMed Web of Science ®Google Scholar
• WILLEM M, GARRATT AN, NOVAK B et al.: Control of peripheral nerve myelination by the β-secretase BACE1. Science (2006) 314:664-666.
   PubMed Web of Science ®Google Scholar
• FRANCIS PT, PALMER AM, SNAPE M, WILCOCK GK: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry (1999) 66:137-147.
   PubMed Web of Science ®Google Scholar
• SARTER M, GEHRING WJ, KOZAK R: More attention must be paid: the neurobiology of attentional effort. Brain Res. Rev. (2006) 51:145-160.
   PubMed Web of Science ®Google Scholar
• MESULAM M: The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn. Mem. (2004) 11:43-49.
   PubMed Web of Science ®Google Scholar
• COLLERTON D: Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience (1986) 19:1-28.
   PubMed Web of Science ®Google Scholar
• DONG H, CSERNANSKY CA, MARTIN MV, BERTCHUME A, VALLERA D, CSERENANSKY JG: Acetylcholinesterase inhibitors ameliorate behavioural deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (2005) 181:145-152.
   PubMed Web of Science ®Google Scholar
• CAPSONI S, UGOLINI G, COMPARINI A, RUBERTI F, BERARDI N, CATTANEO A: Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA (2000) 97:6826-6831.
   PubMed Web of Science ®Google Scholar
• TUSZYNSKI MH, THAL L, PAY M et al.: A Phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. (2005) 11:551-555.
   PubMed Web of Science ®Google Scholar
• SALEHI A, DELCROIX JD, BELICHENKO PV et al.: Increased APP expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 51:29-42.
   PubMed Web of Science ®Google Scholar
• KLEIN J: Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J. Neural Transm. (2000) 107:1027-1063.
   PubMed Web of Science ®Google Scholar
• AULD DS, KORNECOOK TJ, BASTIANETTO S, QUIRION R: Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. (2002) 68:209-245.
   PubMed Web of Science ®Google Scholar
• YAMADA K, NABESHIMA T: Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. (2000) 88:93-113.
   PubMed Web of Science ®Google Scholar
• CHOI SH, PARK CH, KOO JW et al.: Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J. (2001) 15:1816-1818.
   PubMed Web of Science ®Google Scholar
• GAU JT, STEINHILB ML, KAO TC et al.: Stable β-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. (2002) 160:731-738.
   PubMed Web of Science ®Google Scholar
• HARTMANN J, ERB C, EBERT U et al.: Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. Neuroscience (2004) 125:1009-1017.
   PubMed Web of Science ®Google Scholar
• BELLUCCI A, LUCCARINI I, SCALI C et al.: Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol. Dis. (2006) 23:260-272.
   PubMed Web of Science ®Google Scholar
• BALES KR, TZAVARA et, WU S et al.: Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody. J. Clin. Invest. (2006) 116:825-832.
   PubMed Web of Science ®Google Scholar
• CIRRITO JR, MAY PC, O'DELL MA et al.: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. (2002) 23:8844-8853.
   Web of Science ®Google Scholar
• TSANG SW, LAI MK, KIRVELL S et al.: Impaired coupling of M1 muscarinic receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol. Aging (2006) 27:1216-1223.
   PubMed Web of Science ®Google Scholar
• BELL KF, DUCATENZEILER A, RIBEIRO-DA-SILVA A, DUFF K, BENNETT DA, CUELLO AC: The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging (2006) 27:1644-1657.
   PubMed Web of Science ®Google Scholar
• GERMAN DC, YAZDANI U, SPECIALE SG, PASBAKHSH P, GAMES D, LIANG CL: Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. (2003) 462:371-381.
   PubMed Web of Science ®Google Scholar
• ERB C, TROOST J, KOPF S et al.: Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase. J. Neurochem. (2001) 77:638-646.
   PubMed Web of Science ®Google Scholar
• HARTMANN J, KIEWERT C, DUYSEN EG, LOCKRIDGE O, GREIG NH, KLEIN J: Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J. Neurochem. (2007) 100:1421-1429.
   PubMed Web of Science ®Google Scholar
• DEKOSKY ST, IKONOMOVIC MD, STYREN SD et al.: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. (2002) 51:145-155.
   PubMed Web of Science ®Google Scholar
• NITSCH RM, SLACK BE, WURTMAN RJ, GROWDON JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science (1992) 258:304-307.
   PubMed Web of Science ®Google Scholar
• RACCHI M, MAZZUCCHELLI M, LENZKEN SC, PORRELLO E, LANNI C, GOVONI S: Role of acetylcholinesterase inhibitors in the regulation of amyloid β precursor protein (AβPP) metabolism. Chem. Biol. Interact. (2005) 157-158:335-338.
   PubMedGoogle Scholar
• ROBERSON MR, HARRELL LE: Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Rev. (1997) 25:50-69.
   PubMed Web of Science ®Google Scholar
• NI Y, ZHAO X, BAO G et al.: Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation. Nat. Med. (2006) 12:1390-1396.
   PubMed Web of Science ®Google Scholar
• MESHORER E, SOREQ H: Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. (2006) 29:216-224.
   PubMed Web of Science ®Google Scholar
• INESTROSA NC, ALVAREZ A, PEREZ CA et al.: Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron (1996) 16:881-891.
   PubMed Web of Science ®Google Scholar
• REES T, HAMMOND PI, SOREQ H, YOUNKIN S, BRIMIJOIN S: Acetylcholinesterase promotes β-amyloid plaques in cerebral cortex. Neurobiol. Aging (2003) 24:777-787.
   PubMed Web of Science ®Google Scholar
• BARTOLINI M, BERTUCCI C, CAVRINI V, ANDRISANO V: β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. (2003) 65:407-416.
   PubMed Web of Science ®Google Scholar
• CASTRO A, MARTINEZ A: Targeting β-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des. (2006) 12:4377-4387.
   PubMed Web of Science ®Google Scholar
• FRANCIS PT, NORDBERG A, ARNOLD SE: A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol. Sci. (2005) 26:104-111.
   PubMed Web of Science ®Google Scholar
• SHYTLE RD, MORI T, TOWNSEND K et al.: Cholinergic modulation of microglial activation by α7 nicotinic receptors. J. Neurochem. (2004) 89:337-343.
   PubMed Web of Science ®Google Scholar
• PALMER AM: Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci. (2002) 23:426-433.
   PubMed Web of Science ®Google Scholar
• BALLARD CG, GREIG NH, GUILLOZET-BONGAARTS AL, ENZ A, DARVESH S: Cholinesterases: roles in the brain during health and disease. Curr. Alzheimer Res. (2005) 2:307-318.
   PubMedGoogle Scholar
• MARTINEZ A, CASTRO A: Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs (2006) 15:1-12.
   PubMed Web of Science ®Google Scholar
• WILKINSON DG, FRANCIS PT, SCHWAM E, PAYNE-PARRISH J: Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging (2004) 21:453-478.
   PubMed Web of Science ®Google Scholar
• BIRKS J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. (2006):CD005593.
   Google Scholar
• KADUSZKIEWICZ H, ZIMMERMANN T, BECK-BORNHOLDT HP, VAN DEN BH: Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ (2005) 331:321-327.
   PubMed Web of Science ®Google Scholar
• GIACOBINI E: Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res. (2004) 50:433-440.
   PubMed Web of Science ®Google Scholar
• AARSLAND D, MOSIMANN UP, MCKEITH IG: Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J. Geriatr. Psychiatry Neurol. (2004) 17:164-171.
   PubMed Web of Science ®Google Scholar
• GREIG NH, SAMBAMURTI K, YU QS, BROSSI A, BRUINSMA GB, LAHIRI DK: An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. (2005) 2:281-290.
   PubMedGoogle Scholar
• YU Q, HOLLOWAY HW, FLIPPEN-ANDERSON JL, HOFFMAN B, BROSSI A, GREIG NH: Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J. Med. Chem. (2001) 44:4062-4071.
   PubMed Web of Science ®Google Scholar
• AL JAFARI AA, KAMAL MA, GREIG NH, ALHOMIDA AS, PERRY ER: Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. Biochem. Biophys. Res. Commun. (1998) 248:180-185.
   PubMed Web of Science ®Google Scholar
• YU QS, PEI XF, HOLLOWAY HW, GREIG NH, BROSSI A: Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. J. Med. Chem. (1997) 40:2895-2901.
   Google Scholar
• YU Q, HOLLOWAY HW, UTSUKI T, BROSSI A, GREIG NH: Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. (1999) 42:1855-1861.
   PubMed Web of Science ®Google Scholar
• GREIG NH, DE MICHELI E, HOLLOWAY HW et al.: The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol. Scand. Suppl. (2000) 176:74-84.
   PubMedGoogle Scholar
• SKADDAN MB, KILBOURN MR, SNYDER SE, SHERMAN PS: Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. J. Cereb. Blood Flow Metab. (2001) 21:144-148.
   PubMed Web of Science ®Google Scholar
• SKADDAN MB, JEWETT DM, SHERMAN PS, KILBOURN MR: (R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor. Synapse (2002) 45:31-37.
   PubMed Web of Science ®Google Scholar
• IIJIMA S, GREIG NH, GAROFALO P et al.: Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology (1993) 112:415-420.
   PubMed Web of Science ®Google Scholar
• UTSUKI T, UCHIMURA N, IRIKURA M et al.: Pre-clinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition and cognitive efficacy. J. Pharmacol. Exp. Ther. (2007) 321(1):353-361.
   PubMed Web of Science ®Google Scholar
• JANAS AM, CUNNINGHAM SC, DUFFY KB et al.: The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. Life Sci. (2005) 76:1073-1081.
   PubMed Web of Science ®Google Scholar
• IKARI H, SPANGLER EL, GREIG NH et al.: Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neuroreport (1995) 6:481-484.
   PubMed Web of Science ®Google Scholar
• PATEL N, SPANGLER EL, GREIG NH, YU QS, INGRAM DK, MEYER RC: Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport (1998) 9:171-176.
   PubMed Web of Science ®Google Scholar
• MOOR E, AUTH F, DEBOER P, WESTERINK BH: Septal and hippocampal glutamate receptors modulate the output of acetylcholine in hippocampus: a microdialysis study. J. Neurochem. (1996) 67:310-316.
   PubMed Web of Science ®Google Scholar
• ARAUJO JA, STUDZINSKI CM, MILGRAM NW: Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29:411-422.
   PubMed Web of Science ®Google Scholar
• STUDZINSKI CM, ARAUJO JA, MILGRAM NW: The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29:489-498.
   PubMed Web of Science ®Google Scholar
• WALLACE WC, LIEBERBURG I, SCHENK D, VIGO-PELFREY C, DAVIS KL, HAROUTUNIAN V: Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J. Neurosci. (1995) 15:4896-4905.
   PubMed Web of Science ®Google Scholar
• HAROUTUNIAN V, GREIG N, PEI XF et al.: Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res. Mol. Brain Res. (1997) 46:161-168.
   PubMedGoogle Scholar
• LIN L, GEORGIEVSKA B, MATTSSON, ISACSON O: Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc. Natl. Acad. Sci. USA. (1999) 96:12108-12113.
   PubMed Web of Science ®Google Scholar
• SHAW KT, UTSUKI T, ROGERS J et al.: Phenserine regulates translation of β -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA (2001) 98:7605-7610.
   PubMed Web of Science ®Google Scholar
• ROGERS JT, LEITER LM, MCPHEE J et al.: Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J. Biol. Chem. (1999) 274:6421-6431.
   PubMed Web of Science ®Google Scholar
• LAHIRI DK, CHEN D, VIVIEN D, GE YW, GREIG NH, ROGERS JT: Role of cytokines in the gene expression of amyloid β-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J. Alzheimers Dis. (2003) 5:81-90.
   PubMedGoogle Scholar
• LAHIRI DK, FARLOW MR, HINTZ N, UTSUKI T, GREIG NH: Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol. Scand. Suppl. (2000) 176:60-67.
   PubMedGoogle Scholar
• MORSE LJ, PAYTON SM, CUNY GD, ROGERS JT: FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J. Mol. Neurosci. (2004) 24:129-136.
   PubMed Web of Science ®Google Scholar
• LAHIRI DK, CHEN D, MALONEY B et al.: The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther. (2007) 320:386-396.
   PubMed Web of Science ®Google Scholar
• UTSUKI T, YU QS, DAVIDSON D et al.: Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide. J. Pharmacol. Exp. Ther. (2006) 318:855-862.
   PubMed Web of Science ®Google Scholar
• HARTMANN T, BIEGER SC, BRUHL B et al.: Distinct sites of intracellular production for Alzheimer's disease A β40/42 amyloid peptides. Nat. Med. (1997) 3:1016-1020.
   PubMed Web of Science ®Google Scholar
• ROVELET-LECRUX A, HANNEQUIN D, RAUX G et al.: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. (2006) 38:24-26.
   PubMed Web of Science ®Google Scholar
• YU QS, LUO W, HOLLOWAY HW et al.: Racemic N1-norphenserine and its enantiomers: unpredicted inhibition of acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro. Heterocycles (2003) 61:529-539.
   Web of Science ®Google Scholar
• GREIG NH, RUCKLE J, COMER P et al.: Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly individuals. Curr. Alzheimer Res. (2005) 2:483-492.
   PubMedGoogle Scholar
• WINBLAD B, GIACOBINI E, BRUINSMA G, WALTERS E, FRIEDHOFF L: Double-blind placebo-controlled evaluation of the safety and efficacy of phenserine tartrate for the treatment of mild to moderate Alzheimer's disease. 9th International Geneva/Springfield Symposium on Advances in Alzheimer's disease, Geneva, Switzerland (2006):11A (Abstract).
   Google Scholar
• SAMBAMURTI K, ANNAMALAI P, ANITHA S et al.: An acetylcholinesterase inhibitor, phenserine, reduces Aβ1-42 in healthy volunteers. Society for Neuroscience Conference, Atlanta, Georgia, USA (2006):120.11 (Abstract).
   Google Scholar
• CULLEN EI, WALTERS EJ, FRIEDHOFF LT, BRUINSMA GB: A single ascending dose study of the pharmacokinetics and tolerability of posiphen in healthy men and women. Society for Neuroscience Conference, Atlanta, Georgia (USA) (2006):412.10 (Abstract).
   Google Scholar
• CULLEN E, BRUINSMA G, GREIG NH, FRIEDHOFF L, CHEN D, LAHIRI DK: Brain β-amyloid (1-42) in mice treated orally with posiphen tartrate is significantly lower than in vehicle controls. 9th International Geneva/Springfield Symposium on Advances in Alzheimer's disease, Geneva, Switzerland (2006):12A (Abstract).
   Google Scholar
• BEACH TG, HONER WG, HUGHES LH: Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease? Acta Neuropathol. (1997) 93:146-153.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL: Alzheimer's disease. New Engl. J. Med. (2004) 351:56-67.
   PubMed Web of Science ®Google Scholar
• MATTSON MP: Pathways towards and away from Alzheimer's disease? Nature (2004) 430:631-639
   PubMed Web of Science ®Google Scholar
• SAMBAMURTI K, SURAM A, VENUGOPAL C et al.: A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr. Alzheimer Res. (2006) 3:81-90.
   PubMed Web of Science ®Google Scholar
• OHMITSU M, MARUTLE A, NILBRATT M, GREIG N, NORDBERG A, SUGAYA K: Effect of (+)-phenserine treatment in APP23 TG mice transplanted with human neural stem cells. Society for Neuroscience Conference, Atlanta, Georgia, USA (2006):417.5/A5 (Abstract).
   Google Scholar